Untitled design (81).png

Stablepharma Ltd

Membership category
Emerging Y3

4 Queen Street, Bath, BA1 1HE, United Kingdom

Stablepharma Ltd at a glance

StablevaX™ - a vital complementary technology for vaccines

About Stablepharma Ltd

Our novel patented StablevaX™ technology can thermally stabilise and deliver a wide range of vaccines without the requirement for refrigeration. Stablepharma has developed a stabilised vaccine solution that could eliminate the need for the cold chain and enable stockpiling anywhere in the world. StablevaX™ is designed to dramatically enhance the performance of existing and new vaccines. Stablepharma stands to revolutionise the vaccine industry, by helping shield vaccines from temperature-related deterioration and wastage. StablevaX™ has shown strong in-vitro and in-vivo data on stabilising range of vaccines including Tetadif (Td) and naked COVID mRNA. Stablepharma R&D team believe that the StablevaX™ technology could be applicable to over 60 vaccines.

Articles Stablepharma Ltd has contributed to